Literature DB >> 28906116

PhID: An Open-Access Integrated Pharmacology Interactions Database for Drugs, Targets, Diseases, Genes, Side-Effects, and Pathways.

Zhe Deng1, Weizhong Tu1, Zixin Deng1, Qian-Nan Hu1,2.   

Abstract

The current network pharmacology study encountered a bottleneck with a lot of public data scattered in different databases. There is a lack of an open-access and consolidated platform that integrates this information for systemic research. To address this issue, we have developed PhID, an integrated pharmacology database which integrates >400 000 pharmacology elements (drug, target, disease, gene, side-effect, and pathway) and >200 000 element interactions in branches of public databases. PhID has three major applications: (1) assisting scientists searching through the overwhelming amount of pharmacology element interaction data by names, public IDs, molecule structures, or molecular substructures; (2) helping visualizing pharmacology elements and their interactions with a web-based network graph; and (3) providing prediction of drug-target interactions through two modules: PreDPI-ki and FIM, by which users can predict drug-target interactions of PhID entities or some drug-target pairs of their own interest. To get a systems-level understanding of drug action and disease complexity, PhID as a network pharmacology tool was established from the perspective of data layer, visualization layer, and prediction model layer to present information untapped by current databases.

Entities:  

Mesh:

Year:  2017        PMID: 28906116     DOI: 10.1021/acs.jcim.7b00175

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  2 in total

1.  Revealing the efficacy-toxicity relationship of Fuzi in treating rheumatoid arthritis by systems pharmacology.

Authors:  Wuwen Feng; Juan Liu; Dandan Zhang; Yuzhu Tan; Hao Cheng; Cheng Peng
Journal:  Sci Rep       Date:  2021-11-29       Impact factor: 4.379

2.  Systems pharmacology reveals the unique mechanism features of Shenzhu Capsule for treatment of ulcerative colitis in comparison with synthetic drugs.

Authors:  Wuwen Feng; Hui Ao; Shijun Yue; Cheng Peng
Journal:  Sci Rep       Date:  2018-11-01       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.